Cynthia Day, NP
Nurse Practitioner · Lafayette, GANPI 1336424522
Payments from drug & device makers
Across 304 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$978
- Novo Nordisk$703
- Pfizer$340
- Otsuka America Pharmaceutical, Inc.$288
- Bayer$275
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$262
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,488100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 52 | $978 |
| Novo Nordisk | 43 | $703 |
| Pfizer | 21 | $340 |
| Otsuka America Pharmaceutical, Inc. | 15 | $288 |
| Bayer | 13 | $275 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $262 |
| Lilly USA, LLC | 16 | $255 |
| Amgen | 11 | $236 |
| GSK | 15 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $221 |
| AstraZeneca | 13 | $196 |
| Lundbeck LLC | 6 | $145 |
| Boehringer Ingelheim | 7 | $138 |
| Sumitomo Pharma America, Inc. | 7 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $91 |
| Astellas Pharma US Inc | 4 | $88 |
| Merck | 5 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Dexcom, Inc. | 3 | $72 |
| Amarin Pharma, Inc. | 4 | $68 |
| Boston Scientific | 3 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $51 |
| Radius Health, Inc. | 2 | $47 |
| Nevro Corp. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Abbott | 2 | $35 |
| Exact Sciences | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Alkermes, Inc. | 1 | $24 |
| Smith+Nephew | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$5,488 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $55,286 |
| OzempicSemaglutide | 51 | $53,962 |
| JardianceEmpagliflozin | 48 | $45,890 |
| FarxigaDapagliflozin Propanediol | 44 | $40,916 |
| MounjaroTirzepatide | 35 | $37,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $29,423 |
| RybelsusSemaglutide | 23 | $28,739 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $27,698 |
| XareltoRivaroxaban | 21 | $21,702 |
| QuliptaAtogepant | 17 | $20,796 |
| GemtesaVibegron | 24 | $19,258 |
| JanuviaSitagliptin Phosphate | 23 | $18,231 |
| KerendiaFinerenone | 19 | $16,072 |
| VraylarCariprazine Hcl | 11 | $15,716 |
| TrulicityDulaglutide | 11 | $12,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $703 | $82,70174 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $196 | $73,58781 claims |
| PfizerEliquis | $340 | $55,28658 claims |
| Boehringer IngelheimJardiance, Tradjenta | $138 | $52,23160 claims |
| Lilly USA, LLCMounjaro, Trulicity | $255 | $50,41646 claims |
| AbbVieQulipta, Vraylar | $978 | $36,51328 claims |
| GSKTrelegy Ellipta | $223 | $29,42331 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $113 | $19,25824 claims |
| MerckJanuvia | $88 | $18,23123 claims |
| BayerKerendia | $275 | $16,07219 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $10,68214 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $12 | $3,54311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Lafayette
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.